Sarasota, Florida, United States, October 21, 2026
Lakewood-Amedex Biotherapeutics has presented new research highlighting the broad-spectrum antimicrobial activity and low potential for resistance development of Nu-3, its investigational antimicrobial candidate, at IDWeek 2026. The findings highlight the company’s efforts to develop new approaches for treating difficult bacterial infections, particularly infected diabetic foot ulcers (iDFUs), which can pose significant challenges for patients and healthcare professionals. Nu-3 belongs to the company’s proprietary Bisphosphocin® class of antimicrobials and is being developed as a topical treatment intended to eliminate bacteria directly at the infection site. According to the company, laboratory testing demonstrated rapid bactericidal activity against Gram-positive, Gram-negative, and multidrug-resistant bacteria, with bacterial eradication occurring within minutes for the pathogens tested. The research also identified activity against bacterial biofilms, which can contribute to persistent infections and complicate treatment. The findings were presented during IDWeek 2026, taking place in Washington, D.C., from October 21 to 24. While the laboratory results support continued investigation of Nu-3, its clinical effectiveness and safety for infected diabetic foot ulcers must be established through ongoing clinical trials.
Nu-3 Demonstrates Broad-Spectrum Antimicrobial Activity
The research presented at IDWeek examined the antimicrobial properties of Nu-3 against a range of bacterial organisms, including Gram-positive, Gram-negative, and multidrug-resistant pathogens. The candidate demonstrated bactericidal activity in laboratory testing, with rapid bacterial elimination observed for the tested organisms. This broad activity is relevant to wound infections, where different bacterial species and resistance patterns may complicate treatment decisions. The researchers also reported activity against biofilm organisms. Biofilms are structured communities of microorganisms that can attach to surfaces and become more difficult to eliminate than free-floating bacteria. Their presence in chronic wounds can contribute to persistent infection and may reduce the effectiveness of some conventional antimicrobial approaches. Nu-3 is designed for topical delivery, allowing the investigational compound to be applied directly to the affected area. Its development program focuses on evaluating whether this localized approach can help reduce microbial burden while addressing the challenges associated with antimicrobial resistance. These results are based on laboratory studies and do not yet demonstrate clinical benefit in patients. Further clinical evidence will be necessary to determine how the candidate performs in infected wounds under real-world treatment conditions.
Resistance Testing Highlights a Potential Advantage
An important aspect of the presentation was the evaluation of Nu-3’s potential for resistance development. In serial-passage experiments, the company reported only a slight increase in minimum inhibitory concentration (MIC) values against Staphylococcus aureus and Escherichia coli. MIC is the lowest concentration of an antimicrobial agent that prevents visible bacterial growth under defined laboratory conditions. By comparison, the same testing approach showed a 600- to 2,000-fold increase in MIC values for ciprofloxacin. These findings suggest that Nu-3 may have a favorable resistance profile under the experimental conditions examined. However, laboratory serial-passage results cannot establish that resistance will never emerge during clinical use. Continued surveillance and additional studies will be important for understanding the compound’s resistance characteristics. The research is particularly relevant to infected diabetic foot ulcers, where bacterial resistance can complicate infection management and increase the risk of serious complications. The company aims to develop Nu-3 as a potential new topical treatment option for patients whose infections require effective local antimicrobial intervention.
Advertisement
Phase 2a Trial Advances Development for Diabetic Foot Ulcers
Lakewood-Amedex is evaluating Nu-3 in an ongoing Phase 2a clinical trial involving patients with mildly infected diabetic foot ulcers. The study is designed to assess the safety and efficacy of three gel concentrations: 2%, 5%, and 10%. Researchers will examine the candidate’s ability to reduce microbial burden and help resolve infection, while the dose-finding design is intended to guide subsequent clinical development. The company expects topline results from the Phase 2a trial in the first quarter of 2027. These clinical findings will be important in determining whether the encouraging laboratory observations translate into meaningful outcomes for patients. Diabetic foot ulcers can become infected and, in severe cases, contribute to hospitalization, tissue damage, and amputation. The development of new antimicrobial options is therefore an important area of research, particularly as antimicrobial resistance continues to challenge infection management. If clinical results support further development, Nu-3 could advance into subsequent studies to evaluate its treatment potential more extensively. Nu-3 remains investigational and has not been established as an approved treatment for infected diabetic foot ulcers. The ongoing trial represents an important milestone in assessing its potential role in wound care and antimicrobial drug development.
Source: Lakewood-Amedex Biotherapeutics press release
